The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis

Abstract

Background Studies had investigated the associations between proprotein convertase subtilisin/kexin type 9 SNP rs562556 and serum lipids levels and response to statin treatment, however, the results remained inconclusive. We conducted this meta-analysis to elucidate the relationship of rs562556 and serum lipids levels. Methods All eligible studies met the inclusion criteria were retrieved from multiple databases. Relative data were extracted from each study. Review Manager (version 5.3.5) and STATA 12.0 software was used to perform this meta-analysis. Pooled standardized mean difference (SMD) with 95% CI was employed to evaluate the association of rs562556 with serum lipids levels. Results A total of 7 eligible articles involving 4742 subjects were included in the final meta-analysis. The results revealed that the G carriers had lower levels of total cholesterol (SMD: 0.14, 95% Cl: 0.06–0.23, P = 0.001) and LDL-C(SMD: 0.13, 95% Cl: -0.55-0.22, P = 0.002) than the non-carriers. The statistical results also illustrated that the G carriers had lower relative risk (SMD: 1.38, 95% Cl: 1.02–1.85, P = 0.003) than the non-carriers. Conclusions The results of the current meta-analysis for the first time indicated the relevance of rs562556 and lower serum cholesterol levels. Electronic supplementary material The online version of this article (10.1186/s12944-019-1036-1) contains supplementary material, which is available to authorized users.

Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors

“…Two published studies presented significant associations between the rs562556 polymorphism and high levels of lipids in patients with hypercholesterolemia and polycystic ovary syndrome 25 , 26 . Recently, a meta-analysis study summarized that the G carriers of the rs562556 polymorphism had lower TC and LDL-C levels and relative risk than the noncarriers 27 . These findings are in agreement with our results that G carriers of the rs562556 polymorphism tended to have lower LDL-C levels.…”

Polymorphisms of rs2483205 and rs562556 in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene are Associated With Coronary Artery Disease

“…Two published studies have evaluated the associations between the rs562556 polymorphism and high levels of lipids in patients with hypercholesterolemia and polycystic ovary syndrome, respectively 24,25 . Currently, a meta-analysis study proceeded with a pooled analysis and concluded that the G carriers of rs562556 polymorphism had lower TC, LDL-C levels, and relative risk than the non-carriers 26 . These ndings are in agreement with our results.…”

A minor allele of the haplotype located in the 19q13 loci is associated with a decreased risk of hyper-LDL-cholesterolemia, and a balanced diet and high protein intake can reduce the risk

“…LDLR rs6511720 and rs57217136 are involved in enhancer-binding protein sites for a transcription factor for LDLR and participants in this study who carried their minor alleles had increased LDLR expression, which consequently reduces serum LDL concentrations [ 24 ]. G carriers of PCSK9 rs562556 had a lower risk of dyslipidemia including decreased serum LDL concentrations in meta-analysis without separating ethnicities [ 25 ]. Participants with the combination of ATP-binding cassette sub-family G member-5 rs6720173-C, cholesterol 7 alpha-hydroxylase rs3808607-TT, and 7-dehydrocholesterol reductase rs760241-GG genotypes had lower serum LDL concentrations relative to those with opposite genotypes after a blended dairy consumption for 4 weeks (3 servings/day) [ 26 ].…”